✦ LIBER ✦

Major hepatectomies are safe in patients with cholangiocarcinoma and jaundice

✍ Scribed by Joan Figueras; Antoni Codina-Barreras; Santiago López-Ben; Jordi Soriano; Berta Pardina; Laia Falgueras; Ernesto Castro; Silvia Torres-Bahi; Rosa Ortiz; Esther Diaz; Albert Maroto; Eugeni Canals

Book ID: 119647498
Publisher: Elsevier
Year: 2009
Weight: 253 KB
Volume: 86
Category: Article
ISSN: 2173-5077
DOI: 10.1016/s2173-5077(09)70100-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safe and Permissible Limits of Hepatecto

Safe and Permissible Limits of Hepatectomy in Obstructive Jaundice Patients

✍ Tetsuya Takahashi; Shinji Togo; Kuniya Tanaka; Itaru Endo; Yoshiro Fujii; Hirosh 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 104 KB

Major Hepatectomy Is a Safe Modality for

Major Hepatectomy Is a Safe Modality for the Treatment of Intrahepatic Cholangiocarcinoma in Selected Patients Complicated with Cirrhosis

✍ Li, Hao; Wu, Jin-shu; Wang, Xin-tian; Lv, Pin; Liu, Gang; Tian, Bu-ning; Li, Ya- 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 172 KB

Major hepatectomy for peripheral papilla

Major hepatectomy for peripheral papillary cholangiocarcinoma with hilar extension in a patient with situs ambiguous

✍ Mircea Chirica; Marie-Pierre Vullierme; Annie Sibert; Dominique Cazals-Hatem; Br 📂 Article 📅 2005 🏛 Masson Editeur 🌐 French ⚖ 503 KB

Molecular Factors Associated With Recurr

Molecular Factors Associated With Recurrence And Survival Following Hepatectomy In Patients With Intrahepatic Cholangiocarcinoma: A Guide To Adjuvant Clinical Trials

✍ S.C. Schiffman; K.M. McMasters; C.R. Scoggins; R.C. Martin 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Are accelerated infliximab infusions saf

Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?

✍ Shivaram Bhat; Divyesh Sharma; Pauline Doherty; Tony C.K. Tham; Grant R. Caddy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Background: Infliximab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). The manufacturerrecommended administration is over 2 hours followed by 2 hours of patient observation. The data relating to adverse outcomes in patients receiving accelerated infusions for IBD

What Is a Safe Future Liver Remnant Size

What Is a Safe Future Liver Remnant Size in Patients Undergoing Major Hepatectomy for Colorectal Liver Metastases and Treated by Intensive Preoperative Chemotherapy?

✍ Narita, Masato; Oussoultzoglou, Elie; Fuchshuber, Pascal; Pessaux, Patrick; Chen 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 266 KB